Tranylcypromine


Irreversible non-selective MAO inhibitor (amphetamine-related)

A non-hydrazine cyclopropylamine MAOI structurally related to amphetamine; rapid-onset compared to phenelzine.

Abstract

Tranylcypromine ((1S,2R)-2-phenylcyclopropan-1-amine; CAS 155-09-9; molecular formula C9H11N; molecular weight 133.19) is a non-hydrazine cyclopropylamine MAOI approved by the FDA in 1961 under the trade name Parnate. The cyclopropylamine scaffold is structurally related to amphetamine, producing weak monoamine release in addition to MAO inhibition; the result is faster antidepressant onset (1 to 2 weeks) than phenelzine (3 to 6 weeks) and a mildly activating subjective profile. Inhibition of both MAO-A and MAO-B is irreversible, with similar tyramine cheese-effect risk. Plasma half-life is 1.5 to 3.2 hours, but enzyme inhibition persists for 5 to 10 days. The (-)-trans isomer is the predominant active form; clinical preparations are racemic. Hepatic metabolism is minor; the compound is largely excreted unchanged. Approved for major depressive disorder; used in atypical and treatment-resistant depression. Used as a non-hydrazine MAOI reference compound and as a positive control in dopaminergic and norepinephrine release studies.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph